

A PROSPECTIVE, RANDOMIZED TRIAL COMPARING PROPOFOL AND REMIMAZOLAM FOR SEDATION IN ADVANCED ENDOSCOPIC PROCEDURES

Adrian Săftoiu

UEG Week Berlin 2025

Poster

Colorectal

October 5, 2025

A randomized single-blind trial of 100 patients found remimazolam comparable to propofol for sedation in advanced endoscopy with significantly fewer hypotensive episodes and respiratory interventions.

KEY POINTS

- Both remimazolam and propofol provided adequate sedation with no significant difference in procedural success rates in 50 patients per group undergoing ERCP, EUS, or EMR.
- Remimazolam was associated with significantly fewer hypotensive episodes and respiratory interventions compared to propofol ($p < 0.05$ for both).
- Recovery time was comparable between groups, while patient satisfaction was higher with remimazolam and endoscopists reported similar ease of procedure in both arms.
- The authors conclude remimazolam appears to be a safe and effective alternative to propofol with potential role in settings with limited anesthesiology support or higher-risk patients.

VIEW THIS CONTENT ON GUTFLIX

<https://gutflix.eu/search/d/588d34fe-a815-11f0-a59f-0242ac140006>



AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.